[Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease].
A 63-year-old woman with Behçet disease presented with epigastric pain due to refractory gastric ulcers. Examinations indicated that these ulcers were caused by gastrointestinal Behçet disease. Steroid therapy proved ineffective, so we gave 5mg/kg of infliximab. However, since the patient responded poorly to the treatment the infliximab was discontinued and a total gastrectomy was performed. After surgery, a marginal ulcer developed and infliximab was again administered. Although this brought about improvement in the conditions of the marginal ulcer, infusion-related hypersensitivities in the patient caused polyarthralgia. We therefore discontinued the infliximab treatment and began 40 mg of adalimumab every other week. After 3 months of the new treatment, the patient's marginal ulcer completely healed and her epigastric pain disappeared. This case suggests that adalimumab may be as useful as infliximab for treating refractory gastrointestinal Behçet disease.
Department of 3rd Internal Medicine, Obihiro-Kosei General Hospital. yuis0912@sapmed.ac.jp
Yui
Y
Shimizu
Tsuyoshi
T
Takeda
Ryusuke
R
Matsumoto
Kou
K
Yoshida
Junta
J
Nakajima
Tomofumi
T
Atarashi
Hideyuki
H
Yanagisawa
Keisuke
K
Kikuchi
Hideaki
H
Kikuchi
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000601:surgery*; D005260:Female; D005743:Gastrectomy; D005767:Gastrointestinal Diseases / Q000601:surgery*; D006801:Humans; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab